Pet Safety / Compounds / Xylometazoline / Oxymetazoline

Is Xylometazoline / Oxymetazoline safe for dogs and cats?

Moderate risk for pets

Xylometazoline and oxymetazoline are imidazoline α2-adrenergic agonists used as topical nasal decongestants (Afrin, Dristan, Otrivin). These compounds are among the most common small-molecule toxicoses in dogs because nasal spray containers are easily chewed and the drug is rapidly absorbed through oral mucosa. Imidazoline toxicosis in dogs produces a characteristic syndrome: sedation and CNS depression (α2-adrenergic CNS agonism), bradycardia, hypotension (initially), with rebound hypertension in some cases. Mydriasis and respiratory depression may occur. The mechanism differs from pseudoephedrine (stimulant) — imidazolines cause CNS depression, making the toxidrome sedative/depressant rather than stimulant. A single nasal spray (approximately 0.05% oxymetazoline, 2 sprays = approximately 0.1 mg) can produce clinical signs in small dogs (2–5 kg). Clinical signs typically begin within 30–60 minutes and resolve in 6–12 hours with supportive care. Atipamezole (α2-antagonist) has been used as an antidote in veterinary settings for severe imidazoline toxicosis. Treatment for mild-to-moderate cases is supportive: monitoring, warmth, IV fluids for hypotension.

What is xylometazoline / oxymetazoline?

The IUPAC name is 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole;hydrochloride.

Also known as: 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole;hydrochloride, Xylometazoline hydrochloride, Xylometazoline HCl, Neo-Synephrine II.

IUPAC name
2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole;hydrochloride
CAS number
1218-35-5
Molecular formula
C16H25ClN2
Molecular weight
280.83 g/mol
SMILES
CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C.Cl
PubChem CID
5282386

Risk for dogs

Moderate risk

Xylometazoline and oxymetazoline are imidazoline α2-adrenergic agonists used as topical nasal decongestants (Afrin, Dristan, Otrivin). These compounds are among the most common small-molecule toxicoses in dogs because nasal spray containers are easily chewed and the drug is rapidly absorbed through oral mucosa. Imidazoline toxicosis in dogs produces a characteristic syndrome: sedation and CNS depression (α2-adrenergic CNS agonism), bradycardia, hypotension (initially), with rebound hypertension in some cases. Mydriasis and respiratory depression may occur. The mechanism differs from pseudoephedrine (stimulant) — imidazolines cause CNS depression, making the toxidrome sedative/depressant rather than stimulant. A single nasal spray (approximately 0.05% oxymetazoline, 2 sprays = approximately 0.1 mg) can produce clinical signs in small dogs (2–5 kg). Clinical signs typically begin within 30–60 minutes and resolve in 6–12 hours with supportive care. Atipamezole (α2-antagonist) has been used as an antidote in veterinary settings for severe imidazoline toxicosis. Treatment for mild-to-moderate cases is supportive: monitoring, warmth, IV fluids for hypotension.

Risk for cats

Moderate risk

Cats are similarly sensitive to imidazoline toxicosis from xylometazoline and oxymetazoline. The same sedative/bradycardic toxidrome occurs. A particular concern in cats: xylometazoline and oxymetazoline are found in eye whitening drops (Visine Advanced Redness Relief contains tetrahydrozoline, a structurally related imidazoline — these are distinct but toxicologically similar) as well as nasal sprays. 'Visine in cat food' is a documented animal abuse scenario that causes imidazoline toxicosis in cats. Regardless of exposure source, imidazoline toxicosis in cats presents with profound sedation, bradycardia, respiratory depression, and hypothermia. Prompt veterinary care with supportive treatment and monitoring for respiratory compromise is essential. Atipamezole has been used successfully as an antidote in cats with severe imidazoline toxicosis.

Regulatory consensus

1 regulatory bodyhas classified Xylometazoline / Oxymetazoline.

AgencyYearClassificationNotes
FDAOTC (Over-the-Counter)Topical nasal decongestant; not recommended for children under 6 years

Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.

Where pets encounter xylometazoline / oxymetazoline

  • Industrial FacilitiesManufacturing plants, Chemical storage areas, Waste treatment sites
  • Occupational EnvironmentsFactories, Warehouses, Transportation vehicles

Safer alternatives

Lower-risk approaches that achieve a similar outcome to Xylometazoline / Oxymetazoline:

  • Alternative drug class; Non-pharmacological therapy; Lowest effective dose
    Trade-offs: Direct chemical substitution requires verification that the replacement does not introduce new hazards (regrettable substitution). Conduct full hazard assessment of proposed alternative before adoption.
    Relative cost: 1.2-2×

Frequently asked questions

Is xylometazoline / oxymetazoline safe for pets?

Xylometazoline and oxymetazoline are imidazoline α2-adrenergic agonists used as topical nasal decongestants (Afrin, Dristan, Otrivin). These compounds are among the most common small-molecule toxicoses in dogs because nasal spray containers are easily chewed and the drug is rapidly absorbed through oral mucosa. Imidazoline toxicosis in dogs produces a characteristic syndrome: sedation and CNS depression (α2-adrenergic CNS agonism), bradycardia, hypotension (initially), with rebound hypertension in some cases. Mydriasis and respiratory depression may occur. The mechanism differs from pseudoephedrine (stimulant) — imidazolines cause CNS depression, making the toxidrome sedative/depressant rather than stimulant. A single nasal spray (approximately 0.05% oxymetazoline, 2 sprays = approximately 0.1 mg) can produce clinical signs in small dogs (2–5 kg). Clinical signs typically begin within 30–60 minutes and resolve in 6–12 hours with supportive care. Atipamezole (α2-antagonist) has been used as an antidote in veterinary settings for severe imidazoline toxicosis. Treatment for mild-to-moderate cases is supportive: monitoring, warmth, IV fluids for hypotension.

What products contain xylometazoline / oxymetazoline?

Xylometazoline / Oxymetazoline appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).

See Xylometazoline / Oxymetazoline in the pets app

Look up products containing xylometazoline / oxymetazoline, compare to alternatives, and explore the full data record.

Open in pets View raw API data

Sources (3)

  1. US FDA: Oxymetazoline OTC Nasal Decongestant Labeling — Duration Limits, Rhinitis Medicamentosa Warning, and Pediatric Cautions (2021) — regulatory
  2. ASPCA Animal Poison Control Center: Imidazoline Decongestant Toxicosis in Dogs and Cats (Xylometazoline, Oxymetazoline, Tetrahydrozoline) — CNS Depression, Bradycardia, and Atipamezole Reversal (2023) — veterinary
  3. Plumb's Veterinary Drug Handbook (10th ed.) — Imidazoline Toxicosis: α2-Agonist Mechanism and Antidote (Atipamezole) in Companion Animals (2023) — veterinary

Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →